The med-tech biopharmaceutical company, SOM Biotech, has granted a licence agreement with Corino Therapeutics Inc. for its first product SOMO266 for the treatment of TTR Amyloidosis following encouraging Phase 2 study results.
SOM Biotech is a med-tech biopharmaceutical company which specialises in repurposing drugs (using drugs which already exist on the market) for the treatment of rare diseases of the nervous system. It has raised more than $6 million from both public and private capital since it was founded in 2009 in Barcelona, Spain, and is commencing a Series A fundraising which is targeted to top US and European venture investors.
As it achieves its expansion to the United States and grants its first licence, SOM Biotech looks to proceed with clinical trials and expand the company pipeline. The new office in Cambridge, Massachusetts, which is managed by Michael Greenberg, will facilitate the development of two upcoming drugs: SOM3355 for Huntington’s disease and SOM1201 for treating Adrenoleukodystrophy and potentially Adrenomyeloneuropathy. SOM’s impressive portfolio also includes drugs for Muscular Dystrophy and Glioblastoma. The company’s founder and CEO, Dr Raúl Insa, predicts that ‘SOM is entering an aggressive international growth stage to become the world’s leading company in drug repurposing’.
SOM Biotech’s full press release can be found here.
As always, the best place in the UK to get updates on all aspects of Duchenne is the annual Action Duchenne International Conference. This year the event is 10th-12th November at the Hilton Birmingham Metropole.
